Clinical profile of prasugrel, a novel thienopyridine

The PRINCIPLE-TIMI 44 IPA with 20 μmol/L ADP. A, Loading dose phase with prasugrel 60 mg and clopidogrel 600 mg. The primary end point of the loading dose phase is the 6-hour comparison. Black circles and lines indicate prasugrel measurements and treatment periods; gray triangles and lines, clopidogrel measurements and treatment periods. B, Maintenance dose phase with prasugrel 10 mg and clopidogrel 150 mg. The primary end point of the maintenance dose phase is the combined 15- and 29-day comparison. Gray circles and lines indicate prasugrel measurements and treatment periods; black triangles and lines, clopidogrel measurements and treatment periods. Data in both figures are mean ± SD. LSM, Least-squares mean. Reprinted with permission from Circulation, Vol 116, Issue 25, Wiviott SD, Trenk D, Frelinger AL, et al, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial, pp 2923-32, Copyright © 2007 Lippincott, Williams, & Wilkins, www.lww.com. All rights reserved.⁸

Design schema for TRITON-TIMI 38. Shown here is the study design, study population, and drug dosing and scheduling for TRITON-TIMI 38, a randomized, double-blind, double-dummy, parallel-group clinical trial with an active comparator. (Reprinted from American Heart Journal, Vol 152, Issue 4, Wiviott SD, Antman EM, Gibson CM, et al, Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction [TRITON-TIMI 38], pp 627-35, 2006, with permission from Elsevier.¹³)